the harrington story

Harrington Group Ltd is a public company listed on the Australian Stock Exchange (ASX) under the symbol “HGR”. As a publicly listed entity HGR has undergone a number of evolutions moving from an organisation with a diverse portfolio of investments to the present organisation which is clearly focused on the invitro diagnostics market.

Through the acquisition of Sun Biomedical Laboratories Inc (SBL), HGR has acquired a portfolio of unique invitro diagnostic intellectual property with a specific focus and expertise in the use of saliva as the diagnostic medium. The immediate opportunity to be realised through SBL is the global commercialisation of their benchmark oral-fluid illicit drug screening device OraLine which has established an industry benchmark with the most sensitive detection levels particularly for marijuana which is the most commonly consumed illicit substance both in Australia, the United States and throughout Europe.